Oncoprotein Modulation in Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) is dominated by dysregulated oncoproteins which drive cell-cycle progression, inhibit tumour suppressor functions and reshape the tumour microenvironment. Among these oncoproteins, gankyrin stands out as a master regulator: its ankyrin-repeat structure facilitates interactions with p53 and retinoblastoma protein (Rb), promoting their ubiquitylation and proteasomal degradation. This modulation unleashes cyclin-dependent kinases and transcriptional programmes that foster proliferation, resistance to apoptosis and invasive behaviour. Aberrant stabilisation of β-catenin and activation of PI3K/Akt and JNK pathways further amplify oncogenic signalling. Recent efforts have focused on disrupting these protein–protein interfaces, employing small molecules or RNA interference to restore tumour suppressor levels and sensitise HCC cells to chemotherapeutics. In parallel, profiling studies have revealed that gankyrin expression gradually escalates from premalignant cirrhosis to overt carcinoma, underlining its value as both a biomarker and therapeutic target. Elucidation of these regulatory networks offers avenues for precision intervention in HCC, a cancer of pressing global impact.

Research from Nature Portfolio

Investigations have demonstrated that gankyrin is amenable to direct pharmacological inhibition. Structural analyses led to the discovery of a small-molecule binder that docks at the ankyrin-repeat interface of gankyrin, impeding its interaction with p53 and thereby preserving p53-dependent transcription and DNA-damage responses in liver cancer cells. Complementary clinical tissue studies have mapped the progressive elevation of gankyrin across sequential stages of hepatocarcinogenesis, from normal liver through chronic hepatitis and cirrhosis to tumour onset. Immunohistochemical quantification of nuclear and cytoplasmic gankyrin has correlated its abundance with capsular invasion and intrahepatic metastasis, while shRNA-mediated silencing in HCC cell lines curtailed proliferation, migration and anchorage-independent growth, thus reinforcing gankyrin’s dual role as a diagnostic marker and driver of malignancy.

Oncoprotein Modulation in Hepatocellular Carcinoma publication trend

The graph below shows the total number of articles in oncoprotein modulation in hepatocellular carcinoma across all publications each year (not limited to Nature Index journals).

Technical terms

Oncoprotein: A protein whose aberrant expression or function promotes tumourigenesis by driving cell proliferation or survival.

Hepatocellular carcinoma (HCC): The most common form of primary liver cancer, often arising in the context of chronic liver disease.

Ankyrin repeat: A structural motif in proteins that mediates specific protein–protein interactions through tandemly repeated units.

Ubiquitylation: A post-translational modification in which ubiquitin is attached to a substrate protein, commonly marking it for degradation.

Proteasome: A large protease complex that recognises and degrades ubiquitylated proteins, regulating protein turnover and signalling.

References

1. Gankyrin sustains PI3K/GSK-3β/β-catenin signal activation and promotes colorectal cancer aggressiveness and progression. Oncotarget (2016).
2. The oncoprotein p28GANK establishes a positive feedback loop in β-catenin signaling. Cell Research (2011).
3. Gankyrin drives malignant transformation of chronic liver damage-mediated fibrosis via the Rac1/JNK pathway. Cell Death & Disease (2015).
4. Discovery of a small-molecule binder of the oncoprotein gankyrin that modulates gankyrin activity in the cell. Scientific Reports (2016).
5. Gradually elevated expression of Gankyrin during human hepatocarcinogenesis and its clinicopathological significance. Scientific Reports (2014).
6. Small Molecule Cjoc42 Improves Chemo-Sensitivity and Increases Levels of Tumor Suppressor Proteins in Hepatoblastoma Cells and in Mice by Inhibiting Oncogene Gankyrin. Frontiers in Pharmacology (2021).